FDA approves new Dual Bronchodilator – Bevespi
On April 25, 2016, the United States Food and Drug Administration approved a new inhaler called Bevespi Aerosphere™ for long-term maintenance treatment for those with COPD.
What is Bevespi? It contains two different bronchodilators that act to relax muscles that wraps around breathing tubes. One medication is called glycopyrrolate – a muscarinic antagonsit – and the other medication is called formoterol – a beta agonist. The two medications are delivered using a unique co-suspension technology. It is to be used twice a day, 12 hours apart.
Other Dual Bronchodilator Products Bevespi is the fourth dual bronchodilator in a single device approved in the United States. Others dual bronchodilators in order of approval by the FDA are: Anoro Ellipta®, Stiolto Respimat®, and Utibron NeoHaler®. Studies show that using two different bronchodilators are more effective in improving how the lungs work and making it easier to breathe than one bronchodilator.
It is likely that Bevespi Aerosphere™ will be available in pharmacies later this year.
Bevespi is a pressurized metered-dose inhaler